Cargando…

F24. OMEGA-6 PUFA METABOLISM DISTURBED IN PHOSPHO- AND SPHINGOLIPIDS IN NEUROLEPTIC-NAïVE FIRST-EPISODE SCHIZOPHRENIA PATIENTS – A FATTY ACID PROFILING STUDY IN FIVE LIPID FRACTIONS

BACKGROUND: Alterations of polyunsaturated fatty acid (PUFA) levels are a well-replicated finding in schizophrenia research. There is however a controversy about the origin of this abnormality and its importance in the pathogenesis of schizophrenic illness. To investigate the influence of nutrition,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langbein, Kerstin, Fleischer, Christian, Kuhnt, Katrin, Smesny, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888475/ http://dx.doi.org/10.1093/schbul/sby017.555

Ejemplares similares

T25. ALTERATIONS OF PLASMA PHOSPHOLIPID FATTY ACID PROFILES ARE ASSOCIATED WITH LOCAL BRAIN STRUCTURAL ABNORMALITIES IN NEUROLEPTIC NAïVE FIRST-EPISODE PSYCHOSIS PATIENTS
por: Langbein, Kerstin, et al.
Publicado: (2018)

T23. DYNAMICS OF NEURONAL METABOLISM AFTER THE ACUTE ONSET OF PSYCHOSIS – A TWO YEARS FOLLOW-UP 1H/31P-MR-SPECTROSCOPY STUDY IN NEUROLEPTIC NAïVE UHR TRANSITION PATIENTS
por: Smesny, Stefan, et al.
Publicado: (2018)

S150. DOPAMINE SYNTHESIS CAPACITY IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOTIC PATIENTS
por: Sigvard, Anne, et al.
Publicado: (2018)

T165. ULTRA-HIGH FIELD MORPHOMETRY IN DRUG-NAïVE FIRST EPISODE PSYCHOSIS
por: Das, Tushar, et al.
Publicado: (2018)

T164. STRUCTURAL COVARIANCE IN DRUG-NAïVE FIRST EPISODE PSYCHOSIS: AN ULTRA-HIGH FIELD MRI STUDY
por: Das, Tushar, et al.
Publicado: (2018)

O6.3. PATTERNS OF GRAY MATTER ABNORMALITIES IN PATIENTS WITH FIRST-EPISODE AND TREATMENT-NAïVE SCHIZOPHRENIA
por: Li, Mingli, et al.
Publicado: (2018)

T14. HYPOTHALAMIC-PITUITARY-GONADAL AXIS HORMONES IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE OF PSYCHOSIS AND HEALTHY CONTROLS
por: Teresa Pons-Cabrera, Maria, et al.
Publicado: (2020)

S6. SLEEP ENDOPHENOTYPES OF SCHIZOPHRENIA: A HIGH-DENSITY EEG STUDY IN DRUG-NAïVE, FIRST EPISODE PSYCHOSIS PATIENTS
por: Castelnovo, Anna, et al.
Publicado: (2020)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS
por: Cavalcante, Daniel, et al.
Publicado: (2018)

S158. REWARD ALTERATIONS IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE-PSYCHOSIS PATIENTS BEFORE AND AFTER TREATMENT WITH A PARTIAL DOPAMINE AGONIST
por: Tangmose, Karen, et al.
Publicado: (2018)

O3.8. DORSOLATERAL PREFRONTAL CORTEX IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA: DYNAMIC PHASE COHERENCE OF INFRASLOW OSCILLATIONS
por: Das, Tushar, et al.
Publicado: (2018)

T154. WHITE MATTER INTEGRITY, DURATION OF UNTREATED PSYCHOSIS, AND ANTIPSYCHOTIC TREATMENT RESPONSE IN MEDICATION-NAïVE FIRST EPISODE PSYCHOSIS PATIENTS
por: Kraguljac, Nina, et al.
Publicado: (2020)

S209. DRUG-NAïVE FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDERS: PHARMACOLOGICAL TREATMENT PRACTICES IN INPATIENT UNITS IN HUNAN PROVINCE, CHINA
por: Zhu, Mengran, et al.
Publicado: (2020)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

S57. TREATMENT SATISFACTION IN ACUTE PHASE PSYCHOSIS: COMPARISON BETWEEN ANTIPSYCHOTIC NAïVE AND PREVIOUSLY MEDICATED PATIENTS
por: Stabell, Lena, et al.
Publicado: (2018)

F206. A TRANSLATIONAL STUDY OF BEHAVIOR, BRAIN STRUCTURE AND GENE PATHWAY IN ERBB4 KNOCKOUT MICE AND FIRST-EPISODE TREATMENT-NAïVE PATIENTS WITH SCHIZOPHRENIA
por: Zhang, Chengcheng, et al.
Publicado: (2018)

F181. CHANGE IN PREFRONTAL-LIMBIC MORPHOLOGY AND COGNITION IN DRUG-NAïVE FIRST-EPISODE PSYCHOSIS PATIENTS FOLLOWING ATYPICAL ANTIPSYCHOTIC TREATMENT: A BRIEF LONGITUDINAL STUDY
por: Woodward, Melissa, et al.
Publicado: (2018)

Homeostatic Imbalance of Purine Catabolism in First-Episode Neuroleptic-Naïve Patients with Schizophrenia
por: Yao, Jeffrey K., et al.
Publicado: (2010)

F163. STRUCTURAL AND FUNCTIONAL ALTERATIONS IN THE BRAIN DURING WORKING MEMORY IN MEDICATION-NAïVE PATIENTS AT CLINICAL HIGH-RISK FOR PSYCHOSIS
por: Brønnick, Kolbjørn, et al.
Publicado: (2018)

O6.3. ASSOCIATIONS BETWEEN COGNITIVE FUNCTION AND CORTICAL LEVELS OF GLUTAMATE AND GABA IN ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS
por: Bojesen, Kirsten, et al.
Publicado: (2020)

D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients
por: Stenkrona, Per, et al.
Publicado: (2019)

F16. GLUTAMATE AND GABA LEVELS IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS ARE ASSOCIATED WITH TREATMENT OUTCOME AFTER 1.5 AND 6 MONTHS
por: Bojesen, Kirsten, et al.
Publicado: (2018)

O2.2. EVALUATION OF THE RELATIONSHIP BETWEEN GLUTAMATE AND BRAIN CONNECTIVITY IN ANTIPSYCHOTIC-NAïVE FIRST EPISODE PATIENTS – A COMBINED MAGNETIC RESONANCE SPECTROSCOPY AND RESTING STATE FUNCTIONAL CONNECTIVITY MRI STUDY
por: Maximo, Jose, et al.
Publicado: (2020)

M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NAïVE SCHIZOPHRENIA PATIENTS
por: Nielsen, Mette, et al.
Publicado: (2020)

Overconsumption of Omega-6 Polyunsaturated Fatty Acids (PUFAs) versus Deficiency of Omega-3 PUFAs in Modern-Day Diets: The Disturbing Factor for Their “Balanced Antagonistic Metabolic Functions” in the Human Body
por: Mariamenatu, Abeba Haile, et al.
Publicado: (2021)

Omega-3 Index and Anti-Arrhythmic Potential of Omega-3 PUFAs
por: Tribulova, Narcis, et al.
Publicado: (2017)

M143. REGIONAL CEREBRAL BLOOD FLOW IN INITIALLY ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS: EFFECTS OF PARTIAL D2 RECEPTOR AGONISM AND ASSOCIATION WITH SYMPTOM IMPROVEMENT
por: Bojesen, Kirsten, et al.
Publicado: (2020)

Relationships between dorsolateral prefrontal cortex metabolic change and cognitive impairment in first-episode neuroleptic-naive schizophrenia patients
por: Huang, Man-Li, et al.
Publicado: (2017)

F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST
por: Jessen, Kasper, et al.
Publicado: (2018)

S12. A MACHINE LEARNING FRAMEWORK FOR ROBUST AND RELIABLE PREDICTION OF SHORT- AND LONG-TERM CLINICAL RESPONSE IN INITIALLY ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BASED ON MULTIMODAL NEUROPSYCHIATRIC DATA
por: Ambrosen, Karen S, et al.
Publicado: (2020)

Altered functional connectivity links in neuroleptic-naïve and neuroleptic-treated patients with schizophrenia, and their relation to symptoms including volition
por: Pu, Weidan, et al.
Publicado: (2014)

Movement disorders in neuroleptic-naïve patients with schizophrenia spectrum disorders
por: Ayehu, Moges, et al.
Publicado: (2014)

Efficacy of omega-3 PUFAs in depression: A meta-analysis
por: Liao, Yuhua, et al.
Publicado: (2019)

Omega-3 PUFA vs. NSAIDs for Preventing Cardiac Inflammation
por: Ye, Jiayu, et al.
Publicado: (2018)

The Role of Vitamin D and Omega-3 PUFAs in Islet Transplantation
por: Infante, Marco, et al.
Publicado: (2019)

Cheek cell fatty acids reflect n-3 PUFA in blood fractions during linseed oil supplementation: a controlled human intervention study
por: Grindel, Annemarie, et al.
Publicado: (2013)

Schneiderian First Rank Symptoms and Gamma Oscillatory Activity in Neuroleptic Naïve First Episode Schizophrenia: A 192 Channel EEG Study
por: Tikka, Sai Krishna, et al.
Publicado: (2014)

Omega-3 PUFAs Lower the Propensity for Arachidonic Acid Cascade Overreactions
por: Lands, Bill
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_prg06eqv1t6nrff515tqpvuk2d